New open-access journal, Redox Experimental Biology, launched by Bioscientifica

Redox Experimental Medicine is a new, fully open-access, peer-reviewed journal publishing redox research that advances our understanding of the effect of redox processes on human health and disease. Aberrations in redox processes can have a profound impact on the normal physiology of humans, with implications in many diseases. Redox Experimental Medicine will serve as an essential publication for the international scientific community to translate experimental knowledge to redox-based preventive and/or therapeutic interventions, with a view to advancing health. The journal will publish basic and translational articles which have potential therapeutic relevance, as well as pre-clinical and clinical studies. Led by Editor-in-Chief Professor Giuseppe Poli, from the University of Turin, Redox Experimental Medicine’s highly accomplished and internationally diverse Editorial Board will oversee the rigorous yet rapid peer review of articles. In his launch Editorial, Professor Poli explains how the journal focuses on an underserved area, commenting that "the experimental investigation of the pathophysiological role of a single molecule or a molecular pathway is certainly essential, but it cannot stand alone and needs to be part of a more comprehensive study project, taking into account the complex reality of the human organism". Bioscientifica is sponsoring the article publication charge until the end of 2023, enabling Redox Experimental Medicine authors to publish their research on an open-access basis free of charge, offering greater reach and visibility of their work. Redox Experimental Medicine is now open for submissions. Please take a look at the scope for a full list of topics covered by the journal. About Bioscientifica Bioscientifica exists to support biomedicine. Through our publishing expertise we strengthen biomedical communities to advance science and health. Bioscientifica is owned by the UK’s Society for Endocrinology and any profits made through our publications are redistributed to support biomedical research and practice.